Shamburg News · 8-K filed Oct 29, 2026, 7:05 AM EDT

Phathom Pharmaceuticals Reports Q3 2026 Net Revenue of $84.7 Million, Reaffirms FY 2026 Guidance

PHAT · Phathom Pharmaceuticals, Inc.

  • Earnings
  • Financial statements
  • Materiality: high

Phathom Pharmaceuticals reported third quarter 2026 results for the quarter ended September 30, 2026, with product revenue, net of $84.7 million, up from $49.5 million a year earlier. The company reported a net loss of $13.9 million, or $0.16 per share, compared with a net loss of $30.0 million, or $0.41 per share, in the prior-year quarter. Phathom reaffirmed its full-year 2026 guidance, including net revenue of $310-325 million.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001193125-26-436959.

Written from the filing by Shamburg Markets. Figures are as reported by the company.